Author Archive: BIOtechNOW Editor

Uniting To Accelerate Pediatric Medicine

Erik_Halvorsen

Drug companies inherently absorb significant risk when developing compounds and biologics for clinical use. A recent article suggests that only one out of every 12 drugs that enters clinical trials succeeds and the cost of a drug successfully reaching the market now exceeds an average of $5 billion when you add up the cost of all those that failed along the way. For many indications, such as Alzheimer’s and autism, the need for new treatments Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

“Should the USPTO allow the patenting of living organisms?”

shutterstock_1092009

Most people associate patents with mechanical or electronic devices, new chemical substances, intricate machines or other inanimate things. The notion that patents are also available for living things may be puzzling at first. A patent is a form of property right that allows its owner a certain measure of control over how others may make, use or sell the patented invention. Surely the inventor of e.g. a new gyroscope sensor (like those used in Segway Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , ,

CTTI: Use of Central IRBs in Multi-Center Trials to Streamline Clinical Research

Untitled-1

Multi-center clinical trials can provide high-quality, statistically-sound evidence to answer medical questions. Earlier this year, the Clinical Trials Transformation Initiative (CTTI) launched a new tool and provided recommendations to improve the efficiency and quality of multi-center clinical trials. Typically, each participating center submits the study protocol to its institutional review board (IRB). Thus in a multi-center trial, the same protocol is submitted to as many IRBs as there are sites. The process of multiple reviews Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Prosensa’s IPO and the Value of the BIO Investor Forum

Hans Schikan

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Our primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease. We completed an IPO onto NASDAQ in June of this year. Prior to last year’s BIO Investor Forum in San Francisco, we were still in the very Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

NCATS R&D Day Aimed At Linking Investors to Preclinical Drug Development Projects

McKew_115x76

On behalf of the National Center for Advancing Translational Sciences (NCATS), I invite BIO stakeholders to join us for our inaugural “Research & Development Day” September 12 in Cambridge, Mass. Novartis Institutes for Biomedical Research will host the event at which researchers will showcase therapeutic candidates for indications such as sickle cell disease, hereditary inclusion body myopathy, Duchenne muscular dystrophy and cryptococcal meningitis to potential partners. To register and view the agenda, visit https://events-support.com/events/NCATS_RandD_Day. The Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,